CA2392979A1 - 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline crystal - Google Patents
4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline crystal Download PDFInfo
- Publication number
- CA2392979A1 CA2392979A1 CA002392979A CA2392979A CA2392979A1 CA 2392979 A1 CA2392979 A1 CA 2392979A1 CA 002392979 A CA002392979 A CA 002392979A CA 2392979 A CA2392979 A CA 2392979A CA 2392979 A1 CA2392979 A1 CA 2392979A1
- Authority
- CA
- Canada
- Prior art keywords
- crystal
- trifluoromethyl
- formula
- rel
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16805199P | 1999-11-30 | 1999-11-30 | |
US60/168,051 | 1999-11-30 | ||
PCT/IB2000/001650 WO2001040190A1 (en) | 1999-11-30 | 2000-11-14 | 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as cetp inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2392979A1 true CA2392979A1 (en) | 2001-06-07 |
Family
ID=22609901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002392979A Abandoned CA2392979A1 (en) | 1999-11-30 | 2000-11-14 | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline crystal |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1246804A1 (pt) |
JP (1) | JP2003515592A (pt) |
KR (1) | KR20020058057A (pt) |
CN (1) | CN1402711A (pt) |
AP (1) | AP2002002531A0 (pt) |
AU (1) | AU1048801A (pt) |
BG (1) | BG106854A (pt) |
BR (1) | BR0015836A (pt) |
CA (1) | CA2392979A1 (pt) |
CO (1) | CO5271716A1 (pt) |
EA (1) | EA200200510A1 (pt) |
EC (1) | ECSP003792A (pt) |
EE (1) | EE200200277A (pt) |
GT (1) | GT200000199A (pt) |
HU (1) | HUP0203521A2 (pt) |
IL (1) | IL149097A0 (pt) |
IS (1) | IS6338A (pt) |
MA (1) | MA26845A1 (pt) |
MX (1) | MXPA02005354A (pt) |
NO (1) | NO20022558D0 (pt) |
OA (1) | OA12099A (pt) |
PA (1) | PA8506301A1 (pt) |
PE (1) | PE20010904A1 (pt) |
PL (1) | PL355892A1 (pt) |
TN (1) | TNSN00231A1 (pt) |
TR (1) | TR200201446T2 (pt) |
UY (1) | UY26454A1 (pt) |
WO (1) | WO2001040190A1 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
CZ20033341A3 (cs) * | 2001-06-21 | 2004-10-13 | Pfizeráproductsáinc | Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru |
GT200200170A (es) * | 2001-09-28 | 2003-05-23 | Preparacion de inhibidor de cetp anhidro | |
JP2005523262A (ja) | 2002-02-01 | 2005-08-04 | ファイザー・プロダクツ・インク | 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物 |
CA2472028C (en) * | 2002-02-01 | 2010-03-30 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
EP1920766B1 (en) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
SK2332004A3 (en) | 2002-08-30 | 2004-12-01 | Japan Tobacco Inc | Dibenzylamine compound and medicinal use thereof |
MXPA05003456A (es) | 2002-10-04 | 2005-07-05 | Millennium Pharm Inc | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias. |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
DE60323536D1 (de) | 2002-12-20 | 2008-10-23 | Pfizer Prod Inc | Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
CN1795177A (zh) * | 2003-03-28 | 2006-06-28 | 辉瑞产品公司 | 作为治疗动脉粥样硬化和肥胖症的cetp抑制剂的 1 , 2 , 4 , -取代的1,2,3,4,-四氢-和1,2二氢-喹啉以及1, 2 , 3 , 4-四氢-喹喔啉衍生物 |
JP2007501218A (ja) | 2003-08-04 | 2007-01-25 | ファイザー・プロダクツ・インク | 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物 |
JP4773969B2 (ja) | 2003-10-08 | 2011-09-14 | イーライ リリー アンド カンパニー | 脂質代謝異常の治療ための化合物及び方法 |
JP4922924B2 (ja) * | 2004-04-13 | 2012-04-25 | メルク・シャープ・エンド・ドーム・コーポレイション | Cetp阻害薬 |
US20080269284A1 (en) * | 2004-06-24 | 2008-10-30 | Eli Lilly And Company | Compounds and Methods for Treating Dyslipidemia |
WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
WO2006033004A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds as cetp inhibitors |
JP2008543726A (ja) | 2005-02-24 | 2008-12-04 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症性疾患の処置のためのpgd2受容体アンタゴニスト |
WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
CL2008000684A1 (es) | 2007-03-09 | 2008-08-01 | Indigene Pharmaceuticals Inc | Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica. |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
TWI450896B (zh) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | 反式-4-〔〔(5s)-5-〔〔〔3,5-雙(三氟甲基)苯基〕甲基〕(2-甲基-2h-四唑-5-基)胺基〕-2,3,4,5-四氫-7,9-二甲基-1h-1-苯并氮呯-1-基〕甲基〕-環己基羧酸 |
JP6854752B2 (ja) | 2014-07-30 | 2021-04-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Hdl上昇剤又はhdl模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
AU5731098A (en) * | 1997-02-03 | 1998-08-25 | American Home Products Corporation | 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
-
2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/es unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/es unknown
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/hu unknown
- 2000-11-14 IL IL14909700A patent/IL149097A0/xx unknown
- 2000-11-14 EP EP00971662A patent/EP1246804A1/en not_active Withdrawn
- 2000-11-14 EE EEP200200277A patent/EE200200277A/xx unknown
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/es unknown
- 2000-11-14 CA CA002392979A patent/CA2392979A1/en not_active Abandoned
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/ja active Pending
- 2000-11-14 EA EA200200510A patent/EA200200510A1/ru unknown
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/en not_active Application Discontinuation
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/pt not_active IP Right Cessation
- 2000-11-14 CN CN00816463A patent/CN1402711A/zh active Pending
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/ko not_active Application Discontinuation
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/xx unknown
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 PL PL00355892A patent/PL355892A1/xx not_active Application Discontinuation
- 2000-11-28 UY UY26454A patent/UY26454A1/es not_active Application Discontinuation
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/es not_active Application Discontinuation
- 2000-11-29 GT GT200000199A patent/GT200000199A/es unknown
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/es unknown
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/fr unknown
-
2002
- 2002-04-12 IS IS6338A patent/IS6338A/is unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/fr unknown
- 2002-05-29 NO NO20022558A patent/NO20022558D0/no not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
AP2002002531A0 (en) | 2002-06-30 |
PE20010904A1 (es) | 2001-09-10 |
AU1048801A (en) | 2001-06-12 |
HUP0203521A2 (hu) | 2003-02-28 |
IS6338A (is) | 2002-04-12 |
CO5271716A1 (es) | 2003-04-30 |
EA200200510A1 (ru) | 2002-10-31 |
EE200200277A (et) | 2003-10-15 |
OA12099A (en) | 2006-05-04 |
BG106854A (bg) | 2002-12-29 |
MA26845A1 (fr) | 2004-12-20 |
UY26454A1 (es) | 2001-07-31 |
ECSP003792A (es) | 2002-04-23 |
MXPA02005354A (es) | 2002-12-11 |
TNSN00231A1 (fr) | 2002-05-30 |
GT200000199A (es) | 2002-05-23 |
WO2001040190A1 (en) | 2001-06-07 |
EP1246804A1 (en) | 2002-10-09 |
NO20022558L (no) | 2002-05-29 |
KR20020058057A (ko) | 2002-07-12 |
BR0015836A (pt) | 2002-08-06 |
JP2003515592A (ja) | 2003-05-07 |
TR200201446T2 (tr) | 2002-11-21 |
CN1402711A (zh) | 2003-03-12 |
PL355892A1 (en) | 2004-05-31 |
IL149097A0 (en) | 2002-11-10 |
NO20022558D0 (no) | 2002-05-29 |
PA8506301A1 (es) | 2002-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2327029C (en) | Method for making 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline | |
CA2392979A1 (en) | 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline crystal | |
DE69917400T2 (de) | 4-Carboxyamino-2-Methyl-1,2,3,4-Tetrahydrochinoline als CETP-Hemmer | |
DE69926582T2 (de) | Anellierte 4-Carboxyamino-2-Methyl-1,2,3,4-Tetrahydrochinoline als CETP-Hemmer | |
US6147090A (en) | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines | |
CA2344248C (en) | 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors | |
DE69925845T2 (de) | 4-carboxamino-2-subsitutierte-1,2,3,4-tetrahydrochinoline als cetp inhibitoren | |
US5405843A (en) | Quinoline derivatives | |
JP4108129B2 (ja) | Eaaアンタゴニストとしてのテトラヒドロキノリン誘導体 | |
US5204348A (en) | Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components | |
MXPA00011855A (en) | Method for making (-)-(2r,4s)-4- [(3,5-bis- trifluoromethyl-benzyl)- methoxycarbonylamino]- 2-ethyl-6- trifluoromethyl-3,4-dihydro- 2h-quinoline- 1-carboxylic acid ethyl ester | |
CA2090635A1 (en) | Substituted phenylquinazoline derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |